Everhart Financial Group, Inc.
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 1852858
Dublin, OH
Position in SLS
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$4,251,145
+$2,709,746 QoQ
Shares Held
288,018
-21.0% QoQ
Ownership
0.143%
of shares outstanding
% of Portfolio
0.70%
of 13F equity value
Holder Rank
#29
of 189 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Everhart Financial Group, Inc. holds $7,789,396 across 11 Biotechnology names. SLS ranks #1 (54.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLS |
SELLAS Life Sciences Group, Inc.
This page
|
288,018 | $4,251,145 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,566 | $1,274,609 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,646 | $796,525 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
6,995 | $400,253 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
542 | $337,958 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
3,503 | $277,752 | |
| 7 | ONCY |
Oncolytics Biotech Inc
|
140,899 | $133,854 | |
| 8 | DRTS |
Alpha Tau Medical Ltd.
|
10,000 | $125,800 |
All Filings in SLS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,251,145 | 288,018 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $1,541,399 | 364,397 | Shares | Sole | 2026-04-09 | |
| 2025-12-31 | $1,757,634 | 466,216 | Shares | Sole | 2026-01-07 | |
| 2025-09-30 | $533,151 | 331,150 | Shares | Sole | 2025-11-04 | |
| No filing history on record for this holder in this stock. | ||||||